Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport

Kidney International

Volumn 85, Issue 3, 2014, Pages 522-528

  Yeung, Catherine K ^a   Shen, Danny D ^a   Thummel, Kenneth E ^a   Himmelfarb, Jonathan ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

chronic kidney disease; drug excretion; drug metabolism; drug transporter; uremia

Indexed keywords

CYTOCHROME P450; DRUG METABOLIZING ENZYME; ACICLOVIR; ALFUZOSIN; ALISKIREN; APREPITANT; CAPTOPRIL; CEFEPIME; CEFONICID; CEFSULODIN; CEFTIBUTEN; CILASTATIN; CIMETIDINE; DARIFENACIN; DIACEREIN; DULOXETINE; GUANADREL; KETOROLAC; LANTHANUM; MEVINOLIN; MINOXIDIL; OXPRENOLOL; RANOLAZINE; ROSUVASTATIN; SOLIFENACIN; TACROLIMUS; TADALAFIL; TELITHROMYCIN; UNINDEXED DRUG; VALSARTAN; VARDENAFIL; ZIDOVUDINE; DRUG;

CHRONIC KIDNEY DISEASE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; DRUG UPTAKE; ENZYME SUBSTRATE; HUMAN; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; TRANSPORT KINETICS; UREMIA; AREA UNDER THE CURVE; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG HYDROLYSIS; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC POLYMORPHISM; KIDNEY FAILURE; MOUSE; PROTEIN LOCALIZATION; TRANSCRIPTION INITIATION; ANIMAL; CHRONIC KIDNEY FAILURE; LIVER; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; RENAL INSUFFICIENCY, CHRONIC; UREMIA;

EID: 84895100091     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.399     Document Type: Short Survey

References (57)

1. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038-2047
2. MEDPAC. A Data Book: healthcare spending and the Medicare program, 2009
3. Manley HJ, Cannella CA. Nondialysis (home) medication utilization and cost in diabetic and nondiabetic hemodialysis patients. Nephrol News Issues 2005; 19: 27-28
4. Manley HJ, Cannella CA, Bailie GR et al. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis 2005; 46: 669-680
5. Zhang Y, Zhang L, Abraham S et al. Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther 2009; 85: 305-311
6. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4: 1065-1074
7. Naud J, Nolin TD, Leblond FA et al. Current understanding of drug disposition in kidney disease. J Clin Pharmacol 2012; 52: 10S-22S
8. Nolin TD, Frye RF, Le P et al. ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 2009; 20: 2269-2276
9. Sun H, Huang Y, Frassetto L et al. Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 2004; 32: 1239-1246
10. Bauer LA. Clinical pharmacokinetics and pharmacodynamics. In: DiPiro JT, Talbert RL, Yee GC et al. (eds) Pharmacotherapy: A Pathophysiologic Approach, 6th edn. McGraw-Hill: New York, 2005, pp 51-73
11. Paine MF, Hart HL, Ludington SS et al. The human intestinal cytochrome P450 "pie". Drug Metab Dispos 2006; 34: 880-886
12. Yeung CK, Lang DH, Thummel KE et al. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab Dispos 2000; 28: 1107-1111
13. Nolin TD, Naud J, Leblond FA et al. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008; 83: 898-903
14. Dreisbach AW. The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther 2009; 86: 553-556
15. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006; 109: 1-11
16. Kirch W, Ramsch KD, Duhrsen U et al. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res 1984; 4: 381-384
17. Dreisbach AW, Lertora JJ. The effect of chronic renal failure on hepatic drug metabolism and drug disposition. Semin Dial 2003; 16: 45-50
18. Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993; 71: 282-290
19. Uchida N, Kurata N, Shimada K et al. Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn J Pharmacol 1995; 68: 431-439
20. Leber HW, Schutterle G. Oxidative drug metabolism in liver microsomes from uremic rats. Kidney Int 1972; 2: 152-158
21. Guevin C, Michaud J, Naud J et al. Down-regulation of hepatic cytochrome p450 in chronic renal failure: role of uremic mediators. Br J Pharmacol 2002; 137: 1039-1046
22. Michaud J, Dube P, Naud J et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 2005; 144: 1067-1077
23. Michaud J, Nolin TD, Naud J et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008; 108: 157-163
24. Miyamoto T, Carrero JJ, Stenvinkel P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 2011; 20: 662-668
25. Nolin TD. Altered nonrenal drug clearance in ESRD. Curr Opin Nephrol Hypertens 2008; 17: 555-559
26. Pichette V, Leblond FA. Drug metabolism in chronic renal failure. Curr Drug Metab 2003; 4: 91-103
27. Michaud J, Naud J, Chouinard J et al. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2006; 17: 3041-3048
28. Morgan ET, Goralski KB, Piquette-Miller M et al. Regulation of drugmetabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36: 205-216
29. Schmiedlin-Ren P, Thummel KE, Fisher JM et al. Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab Dispos 2001; 29: 1446-1453
30. Toell A, Degenhardt S, Grabensee B et al. Inhibitory effect of uremic solutions on protein-DNA-complex formation of the vitamin D receptor and other members of the nuclear receptor superfamily. J Cell Biochem 1999; 74: 386-394
31. Jones SA, Moore LB, Shenk JL et al. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol Endocrinol 2000; 14: 27-39
32. Bogaards JJ, Bertrand M, Jackson P et al. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 2000; 30: 1131-1152
33. Nolin TD, Frye RF, Matzke GR. Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 2003; 42: 906-925
34. Terao N, Shen DD. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther 1985; 233: 277-284
35. Roskos LK. Inhibition of the hepatic metabolism of (S)-propranolol by uremic blood constituents. Ph.D. Thesis. University of Washington: Seattle, 1994
36. Yoshitani T, Yagi H, Inotsume N et al. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull 2002; 25: 1077-1083
37. Taburet AM, Vincent I, Perello L et al. Impairment of drug biotransformation in renal disease: An in vitro model. Clin Pharmacol Ther 1996; 59: 136
38. Bianchetti G, Graziani G, Brancaccio D et al. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet 1976; 1: 373-384
39. Shi J, Montay G, Chapel S et al. Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment. J Clin Pharmacol 2004; 44: 234-244
40. Yang J, Liao M, Shou M et al. Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 2008; 9: 384-394
41. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP 1991; 25: 1214-1224
42. Korzekwa KR, Krishnamachary N, Shou M et al. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998; 37: 4137-4147
43. Tang W, Stearns RA. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2001; 2: 185-198
44. Leblond F, Guevin C, Demers C et al. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2001; 12: 326-332
45. Leblond FA, Petrucci M, Dube P et al. Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 2002; 13: 1579-1585
46. Fenner KS, Jones HM, Ullah M et al. The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance. Xenobiotica 2012; 42: 28-45
47. Bowmer CJ, Yates MS. Pharmacokinetics and biliary excretion of bromosulphophthalein, [3 H]-ouabain and [3H]-taurocholic acid in rats with glycerol-induced acute renal failure. Br J Pharmacol 1984; 83: 773-782
48. Yates MS, Bowmer CJ, Emmerson J. Effect of acute renal failure on the clearance and biliary excretion of indocyanine green in perfused rat liver. Biochem Pharmacol 1984; 33: 1695-1696
49. Sun H, Frassetto LA, Huang Y et al. Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther 2010; 87: 465-472
50. Sun H, Huang Y, Okochi H et al. Uremic toxins inhibit hepatic uptake of eprosartan. Clin Pharmacol Ther 2005; 77: 2
51. Tsujimoto M, Kinoshita Y, Hirata S et al. Effects of uremic serum and uremic toxins on hepatic uptake of digoxin. Ther Drug Monit 2008; 30: 576-582
52. Vanholder R, De Smet R, Glorieux G et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
53. Govindarajan R, Endres CJ, Whittington D et al. Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes. Am J Physiol Gastrointestinal Liver Physiol 2008; 295: G570-G580
54. Hoffmaster KA, Turncliff RZ, LeCluyse EL et al. P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 2004; 21: 1294-1302
55. LeCluyse EL, Fix JA, Audus KL et al. Regeneration and maintenance of bile canalicular networks in collagen-sandwiched hepatocytes. Toxicol In Vitro 2000; 14: 117-132
56. Huh D, Torisawa YS, Hamilton GA et al. Microengineered physiological biomimicry: organs-on-chips. Lab Chip 2012; 12: 2156-2164
57. Zheng Y, Chen J, Craven M et al. In vitro microvessels for the study of angiogenesis and thrombosis. Proc Natl Acad Sci U S A 2012; 109: 9342-9347.